CFO and Treasurer of Orexigen Therapeutics Inc. (OREX, Financial) Graham K Cooper sells 82,500 shares of OREX on 12/21/2009 at an average price of $8.22 a share.
OREXIGEN THERAPEUTICS, INC. is a biopharmaceutical company focused on the development of pharmaceutical product candidates for the treatment of central nervous system disorders, including obesity. The Company's lead combination product candidates targeted for obesity are Contrave, which is in Phase III clinical trials, and Empatic, which is in the later stages of Phase II clinical development. Both product candidates are designed to take advantage of the Company's understanding of how the brain appears to regulate appetite and energy expenditure, as well as the mechanisms that come into play to limit weight loss over time. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss. Orexigen Therapeutics Inc. has a market cap of $397.5 million; its shares were traded at around $8.45 with and P/S ratio of 4516.9.
OREX is in the portfolios of Jean-Marie Eveillard of Arnhold & S. Bleichroeder Advisers, LLC.
OREXIGEN THERAPEUTICS, INC. is a biopharmaceutical company focused on the development of pharmaceutical product candidates for the treatment of central nervous system disorders, including obesity. The Company's lead combination product candidates targeted for obesity are Contrave, which is in Phase III clinical trials, and Empatic, which is in the later stages of Phase II clinical development. Both product candidates are designed to take advantage of the Company's understanding of how the brain appears to regulate appetite and energy expenditure, as well as the mechanisms that come into play to limit weight loss over time. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss. Orexigen Therapeutics Inc. has a market cap of $397.5 million; its shares were traded at around $8.45 with and P/S ratio of 4516.9.
OREX is in the portfolios of Jean-Marie Eveillard of Arnhold & S. Bleichroeder Advisers, LLC.
Directors and Officers Recent Trades:
- Buy:: 10% Owner Parters Vii L P Domain bought 135,784 shares of OREX stock on 12/18/2009 at the average price of 7.54, the price of the stock has increased by 12.07% since.
- Buy:: 10% Owner Kathleen K Schoemaker bought 138,100 shares of OREX stock on 12/18/2009 at the average price of 7.54, the price of the stock has increased by 12.07% since.
- Buy:: 10% Owner Nicole Vitullo bought 138,100 shares of OREX stock on 12/18/2009 at the average price of 7.54, the price of the stock has increased by 12.07% since.
- Buy:: 10% Owner Brian K Halak bought 138,100 shares of OREX stock on 12/18/2009 at the average price of 7.54, the price of the stock has increased by 12.07% since.
- Buy:: 10% Owner Kathleen K Schoemaker bought 138,100 shares of OREX stock on 12/18/2009 at the average price of 7.54, the price of the stock has increased by 12.07% since.
